CALLIDITAS THERAPEUTICS AB

Analyst Reco. Calliditas Therapeutics AB

Equities

CALTX

SE0010441584

Market Closed - Nasdaq Stockholm Other stock markets 11:29:42 2024-05-31 am EDT			5-day change	1st Jan Change
208.2 ^SEK	+0.10%		+81.83%	+63.81%

May. 31	Citigroup Downgrades Calliditas Therapeutics to Neutral From Buy, Price Target at $39	MT
May. 31	Calliditas Partner Secures European Panel Backing for Rare Kidney Disease Treatment	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Citigroup Downgrades Calliditas Therapeutics to Neutral From Buy, Price Target at $39	May. 31	MT
HC Wainwright Downgrades Calliditas Therapeutics to Neutral From Buy, Cuts Price Target to $39 From $45	May. 28	MT
Stifel Downgrades Calliditas Therapeutics to Hold From Buy, Cuts Price Target to $40 From $55	May. 28	MT
HC Wainwright Cuts Calliditas Therapeutics Price Target to $45 From $50, Maintains Buy Rating	May. 24	MT
Guggenheim Adjusts Calliditas Therapeutics' Price Target to $18 From $21, Keeps Neutral Rating	23-08-18	MT
HC Wainwright Initiates Coverage on Calliditas Therapeutics With Buy Rating, $60 Price Target	23-06-20	MT
Guggenheim Initiates Calliditas Therapeutics at Neutral With $18 Price Target	23-03-01	MT
HC Wainwright Adjusts Calliditas Therapeutics' Price Target to $62 From $52, Reiterates Buy Rating	21-12-20	MT
Citigroup Adjusts Calliditas Therapeutics' Price Target to $84 From $51, Reiterates Buy Rating	21-12-20	MT
ANALYST RECOMMENDATIONS : Alibaba, Goldman Sachs, Monday.com, Shaftesbury, 3M Company...	21-07-07

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

All transcripts on over 9000 companies, on the day they post their earnings!

Unlock them now!

fermer